<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Psychiatry</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">2168-622X</issn><issn pub-type="epub">2168-6238</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10034668</article-id><article-id pub-id-type="pmcid-ver">PMC10034668.1</article-id><article-id pub-id-type="pmcaid">10034668</article-id><article-id pub-id-type="pmcaiid">10034668</article-id><article-id pub-id-type="pmid">36947029</article-id><article-id pub-id-type="doi">10.1001/jamapsychiatry.2023.0234</article-id><article-id pub-id-type="publisher-id">yoi230009</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="domain" specific-use="print"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-first"><subject>Online First</subject></subj-group><subj-group subj-group-type="allowCommenting"><subject>Comments</subject></subj-group></article-categories><title-group><article-title>Association of Patients&#8217; Direct Addition of Buprenorphine to Urine Drug Test Specimens With Clinical Factors in Opioid Use Disorder</article-title><alt-title alt-title-type="headline">Patients&#8217; Direct Addition of Buprenorphine to Urine Drug Test Specimens and Clinical Factors in Opioid Use Disorder</alt-title><alt-title alt-title-type="running-head">Patients&#8217; Direct Addition of Buprenorphine to Urine Drug Test Specimens and Clinical Factors in Opioid Use Disorder</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Pytell</surname><given-names initials="JD">Jarratt D.</given-names></name><degrees>MD</degrees><degrees>MHS</degrees><xref rid="yoi230009aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Whitley</surname><given-names initials="P">Penn</given-names></name><degrees>BA</degrees><xref rid="yoi230009aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Passik</surname><given-names initials="SD">Steven D.</given-names></name><degrees>PhD</degrees><xref rid="yoi230009aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bundy</surname><given-names initials="WL">William L.</given-names></name><degrees>PharmD</degrees><xref rid="yoi230009aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dawson</surname><given-names initials="E">Eric</given-names></name><degrees>PharmD</degrees><xref rid="yoi230009aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saloner</surname><given-names initials="B">Brendan</given-names></name><degrees>PhD</degrees><xref rid="yoi230009aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="yoi230009aff1"><label>1</label>Department of Medicine, University of Colorado School of Medicine, Aurora</aff><aff id="yoi230009aff2"><label>2</label>Millennium Health, San Diego, California</aff><aff id="yoi230009aff3"><label>3</label>Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> January 26, 2023.</p><p content-type="published-online"><bold>Published Online:</bold> March 22, 2023. doi:<uri content-type="doi">10.1001/jamapsychiatry.2023.0234</uri></p><corresp id="yoi230009cor1"><bold>Corresponding Author:</bold> Jarratt D. Pytell, MD, MHS, Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Mail Stop B180, 12631 E 17th Ave, Aurora, CO 80045 (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jarratt.pytell@cuanschutz.edu">jarratt.pytell@cuanschutz.edu</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Mr Whitley had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic toggle="yes">Concept and design:</italic> All authors.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> Pytell, Whitley, Passik, Dawson, Saloner.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> Pytell, Whitley, Passik, Bundy, Dawson.</p><p><italic toggle="yes">Critical revision of the manuscript for important intellectual content:</italic> All authors.</p><p><italic toggle="yes">Statistical analysis:</italic> Pytell, Whitley, Passik.</p><p><italic toggle="yes">Administrative, technical, or material support:</italic> Bundy, Dawson.</p><p><italic toggle="yes">Supervision:</italic> Dawson.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Saloner reported conducting this research in collaboration with Millennium Health through an unpaid consulting agreement. Dr Saloner received grants from the National Institute on Drug Abuse during the conduct of this study. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> This study was supported by <funding-source rid="sp1">Millennium Health</funding-source>.</p><p><bold>Role of the Funder/Sponsor:</bold> Millennium Health provided technical assistance on the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-YOI230009-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p><p><bold>Additional Contributions:</bold> We acknowledge Ashish Thakrar, MD (University of Pennsylvania), for his thoughtful discussions of the project; compensation was not received.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2023-03-22T10:00"><day>22</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2023</year></pub-date><volume>80</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">431897</issue-id><fpage>459</fpage><lpage>467</lpage><history><date date-type="received"><day>28</day><month>9</month><year>2022</year></date><date date-type="accepted"><day>26</day><month>1</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>03</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>22</day><month>03</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-03-22 00:25:14.460"><day>22</day><month>03</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright 2023 American Medical Association. All Rights Reserved.</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jamapsychiatry-e230234.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jamapsychiatry-e230234.pdf">jamapsychiatry-e230234.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/journals/archpsyc/fullarticle/10.1001/jamapsychiatry.2023.0234"/><abstract abstract-type="teaser" specific-use="electronic"><p>This cross-sectional study characterizes factors associated with the direct addition of buprenorphine to urine specimens in individuals prescribed buprenorphine for opioid use disorder.</p></abstract><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-yoi230009-1"><title>Question</title><p>What factors are associated with patients&#8217; direct addition of buprenorphine to urine drug test specimens among patients prescribed buprenorphine for opioid use disorder?</p></sec><sec id="ab-yoi230009-2"><title>Findings</title><p>In this cross-sectional study of 507&#8201;735 urine specimens, 1.9% had evidence that patients directly added buprenorphine to the specimen. Specimens suggestive of the direct addition of buprenorphine were more likely to be positive for nonprescribed opioids and collected in primary care settings.</p></sec><sec id="ab-yoi230009-3"><title>Meaning</title><p>These findings suggest that the direct addition of buprenorphine to specimens is a clinically relevant finding and highlight the need for best practices tailored to care settings.</p></sec></abstract><abstract><sec id="ab-yoi230009-4"><title>Importance</title><p>The direct addition of buprenorphine to urine drug test specimens to mimic results suggestive of adherence is a clinically significant result, yet little is known about the phenomenon.</p></sec><sec id="ab-yoi230009-5"><title>Objective</title><p>To characterize factors associated with the direct addition of buprenorphine to urine specimens among patients prescribed buprenorphine for opioid use disorder.</p></sec><sec id="ab-yoi230009-6"><title>Design, Setting, and Participants</title><p>This cross-sectional study of urine drug test specimens was conducted from January 1, 2017, to April 30, 2022, using a national database of urine drug test specimens ordered by clinicians from primary care, behavioral health, and substance use disorder treatment clinics. Urine specimens with quantitative norbuprenorphine and buprenorphine concentrations from patients with opioid use disorder currently prescribed buprenorphine were analyzed.</p></sec><sec id="ab-yoi230009-7"><title>Exposures</title><p>Nonprescribed opioid or stimulant co-positive, clinical setting, collection year, census division, patient age, patient sex, and payor.</p></sec><sec id="ab-yoi230009-8"><title>Main Outcomes and Measures</title><p>Norbuprenorphine to buprenorphine ratio less than 0.02 identified direct addition of buprenorphine. Unadjusted trends in co-positivity for stimulants and opioids were compared between specimens consistent with the direct addition of buprenorphine. Factors associated with the direct addition of buprenorphine were examined with generalized estimating equations.</p></sec><sec id="ab-yoi230009-9"><title>Results</title><p>This study included 507&#8201;735 urine specimens from 58&#8201;476 patients. Of all specimens, 261&#8201;210 (51.4%) were obtained from male individuals, and 137&#8201;254 (37.7%) were from patients aged 25 to 34 years. Overall, 9546 (1.9%) specimens from 4550 (7.6%) patients were suggestive of the direct addition of buprenorphine. The annual prevalence decreased from 2.4% in 2017 to 1.2% in 2020. Opioid-positive with (adjusted odds ratio [aOR], 2.01; 95% CI, 1.85-2.18) and without (aOR, 2.02; 95% CI, 1.81-2.26) stimulant-positive specimens were associated with the direct addition of buprenorphine to specimens, while opioid-negative/stimulant-positive specimens were negatively associated (aOR, 0.78; 95% CI, 0.71-0.85). Specimens from patients aged 35 to 44 years (aOR, 1.59; 95% CI, 1.34-1.90) and primary care (aOR, 1.60; 95% CI, 1.44-1.79) were associated with the direct addition of buprenorphine. Differences by treatment setting decreased over time. Specimens from the South Atlantic census region had the highest association (aOR, 1.4; 95% CI, 1.25-1.56) and New England had the lowest association (aOR, 0.54; 95% CI, 0.46-0.65) with the direct addition of buprenorphine.</p></sec><sec id="ab-yoi230009-10"><title>Conclusions and Relevance</title><p>In this cross-sectional study, the direct addition of buprenorphine to urine specimens was associated with other opioid positivity and being collected in primary care settings. The direct addition of buprenorphine to urine specimens is a clinically significant finding, and best practices specific for this phenomenon are needed.</p></sec></abstract><funding-group><award-group><funding-source id="sp1">Millennium Health</funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>